Catalyst Pharma to acquire U.S. rights of FYCOMPA from Eisai for $160M upfront

CATALYST PHARMACEUTICALS, INC.

$160M upfront at closing; potential $25M milestone if patent exclusivity extended to June 2026.
FYCOMPA U.S. net revenues approx. $136M for Eisai fiscal year ending March 2023.
Deal expected to be EBITDA and EPS accretive in 2023; all-cash, no financing contingencies.
Includes exclusive option to evaluate and negotiate acquisition of a rare epilepsy pipeline asset.
Expected close Q1 2023, subject to customary closing conditions and U.S. regulatory clearances.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

CATALYST PHARMACEUTICALS, INC. entered into Asset Purchase Agreement with Eisai Co., Ltd valued at $160 million (effective 2022-12-17).

Action: entry
Agreement: asset purchase
Counterparty: Eisai Co., Ltd
Value: $160 million
Effective: 2022-12-17

Exact text from the filing

On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Eisai Co., Ltd (“ Eisai ”), pursuant to which the Company has agreed to acquire from Eisai the U.S. rights for FYCOMPA ® (perampanel) CIII.

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-311070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.